Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. - Wikidata - awgldk - TriplyDB

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.

http://www.wikidata.org/entity/Q34309832

about

Emerging PSA-based tests to improve screening Nanobodies as novel agents for cancer therapy.A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Göteborg, Sweden.Does prostate growth confound prostate specific antigen velocity? Data from the Baltimore longitudinal study of aging.Alterations in the serum glycome due to metastatic prostate cancer A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam.Prospective validation of %p2PSA and the Prostate Health Index, in prostate cancer detection in initial prostate biopsies of Asian men, with total PSA 4-10 ng ml-1.A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication.Clinical use of [-2]proPSA (p2PSA) and its derivatives (%p2PSA and Prostate Health Index) for the detection of prostate cancer: a review of the literature Glycoproteomics for prostate cancer detection: changes in serum PSA glycosylation patterns.Natural and synthetic inhibitors of kallikrein-related peptidases (KLKs).Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).A multicenter study of [-2]pro-prostate specific antigen combined with prostate specific antigen and free prostate specific antigen for prostate cancer detection in the 2.0 to 10.0 ng/ml prostate specific antigen range.Applicability of biomarkers in the early diagnosis of prostate cancer.Distribution and associations of [-2]proenzyme-prostate specific antigen in community dwelling black and white men PSA, PSA derivatives, proPSA and prostate health index in the diagnosis of prostate cancer.A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy.[-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements.Can one blood draw replace transrectal ultrasonography-estimated prostate volume to predict prostate cancer risk?Systematic, evidence-based discovery of biomarkers at the NCI.Differentiation of lethal and non lethal prostate cancer: PSA and PSA isoforms and kinetics.[-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study.Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa)Prospective evaluation of operating characteristics of prostate cancer detection biomarkers.Potential clinical importance of the activation peptide of prostate-specific antigen The Prostate Health Index: a new test for the detection of prostate cancer.Diagnostic ability of %p2PSA and prostate health index for aggressive prostate cancer: a meta-analysis.From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer.Next-generation prostate-specific antigen test: precursor form of prostate-specific antigen.Current biomarkers for diagnosing of prostate cancer.Blood-based and urinary prostate cancer biomarkers: a review and comparison of novel biomarkers for detection and treatment decisions.On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA.Improving multivariable prostate cancer risk assessment using the Prostate Health Index.Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.Diagnostic Performance of %[-2]proPSA and Prostate Health Index for Prostate Cancer: Prospective, Multi-institutional Study.The Use of Biomarkers in Prostate Cancer Screening and Treatment.

P2860

Q26828563-0908B1AC-E955-46C6-8FD2-875BB4FD813E Q30778309-ED0B5301-0B34-4436-9F3F-3213D04B913A Q31161981-04ABF426-0398-4633-ADAC-621BFD578235 Q31171895-3D7ED010-2216-4302-A2B9-870310938645 Q33282042-5A7E2699-FDC1-4601-9AB1-180FC6308EBF Q33558289-0FA205A1-0D60-4F41-8D8E-012D43193F79 Q33668692-D46A1D90-C7F6-4F0A-8BAA-31D31E93ACC6 Q33839248-02E414B1-956D-43F6-8517-830C05E161CF Q33897630-E607BD4A-AF95-4833-AB1D-5894869B4C87 Q33911725-5066761D-2C67-439E-940B-4760D0F884A3 Q34381513-0AE6901A-9420-4F9B-B4B6-D8FFA0CFBE07 Q34457491-645CC4A4-2060-4EC9-B555-EACBE8C4AC1B Q34751961-15D0ABA1-143A-4539-A37F-465D3022EAD2 Q35119292-911C012A-BB59-4E21-8062-8785B8984262 Q35821838-26EFDB78-7E9F-4FBB-8E62-B0D3E1198438 Q35838396-D16DB063-D6B5-45EC-9288-953A14815F99 Q35993261-618AB1F7-3084-4C8C-A511-DB4744B4DC4E Q35995359-8AF0E554-083D-45D7-B2D1-BF7358EF2A4A Q36509148-2534D880-9317-451D-BB48-C3BCA5D6513B Q36616932-81AAC207-7E6A-4AEE-A979-D7A93529AFE9 Q36909145-AE7D7E4C-6BB3-4EA7-96FD-C0F511230D64 Q36922015-1970F456-C7F8-46A2-B3A3-74ABC317B5F3 Q37037804-1B1CCD82-F5FB-4899-BEB0-5D43316EAAE3 Q37108081-0619B7F5-A9BE-4B50-AEE8-AB9DD37CE40F Q37155070-C227472A-6472-428D-BAAF-F5274B72763D Q37252155-37345F85-B24B-43CF-A5B8-CA212019D253 Q37268890-5391E71F-6404-4AC9-8AA4-6170C1BF186F Q37619016-64FCAE36-CA44-469B-A8A3-4A9BF64A31DA Q37738370-DD57EE31-8089-4539-A30B-71010B970C78 Q38023597-FE80652C-FE0A-48CD-A8DB-9BD9A9E21E83 Q38241107-77ED78DB-A467-484C-BFFB-183FECFA9CAD Q38584370-37974653-A73E-4F91-BF0F-647A308F9DEB Q38786630-A3B1EA1D-ED54-49EB-B235-CB12880E71AE Q39378788-69099656-2AE3-4DF2-B169-A6BF14013B12 Q40270088-4A6096CD-A8B2-4029-84E5-E6666CA03213 Q43075907-22B12BE0-384A-41E3-B1AD-E4A0E88DB010 Q52679257-2A5F57C5-C590-4536-A7CA-CB590833EC9A Q52689045-88567035-49D8-411F-8D7C-BDBF5A0837FC

P2860

Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer.

http://www.wikidata.org/entity/Q34309832

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

name

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@ast

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@en

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@nl

type

label

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@ast

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@en

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@nl

prefLabel

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@ast

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@en

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@nl

P1433

Q34309832-BA047882-A83C-41F3-B65E-953F8E26CBC5

P1476

Q34309832-50C983C8-D5B7-4C86-9DCE-17AB83459EBE

P2093

Q34309832-4505AF21-F96A-4652-B205-45DEEDAB0D67

Q34309832-4F3C1887-D56D-4F54-BB8C-030264C6BA24

Q34309832-6CB5C73D-EEAC-4EC4-8AEF-77DBD0066DED

Q34309832-7E9EDC75-7D02-4780-B4BB-EEDBB81A5D81

Q34309832-98382436-9666-49B0-8DAF-ECADD7212398

Q34309832-E06B3079-6243-454C-9BEE-A1F83D9D4700

Q34309832-E421AE0D-8560-4B86-97A0-32CBD83DA4F6

Q34309832-ED0D804C-9E9F-45D6-A883-9AA66F6DEE4F

Q34309832-F99BDF5A-0248-4343-A996-96308F0BA158

P304

Q34309832-C2F48492-C701-46E1-9450-A4D02D2C8D19

P31

Q34309832-19E7BFE9-02DB-4610-99E5-F35C45727941

P356

Q34309832-CA4A500D-C4F7-4A40-B069-033E6E9343C6

P407

Q34309832-7A4CB02A-E0C8-49BD-8780-2FE920106090

P433

Q34309832-9D4BCFBA-F5D7-4D90-8EBA-52031B4DEE74

P478

Q34309832-2BC7C7C7-521F-4998-A880-6988AB47B09C

P577

Q34309832-CD999039-C458-4585-BB2D-673D343E7ADD

P5875

Q34309832-D82A6A73-C6AE-4EB8-83D8-352909D188CB

P698

Q34309832-52F4DE7D-F696-45A7-9D24-876EC73F5939

P921

Q34309832-2AE9ACEB-C038-4265-B5AE-734C97460E2E

P356

CLINCHEM.2003.026823

P1433

Clinical Chemistry

P1476

Proenzyme forms of prostate-sp ...... detection of prostate cancer.

@en

P2093

Anna Amirkhan

http://www.w3.org/2001/XMLSchema#string

Cindy L Evans

http://www.w3.org/2001/XMLSchema#string

Diksha Katir

http://www.w3.org/2001/XMLSchema#string

Harry G Rittenhouse

http://www.w3.org/2001/XMLSchema#string

Harry J Linton

http://www.w3.org/2001/XMLSchema#string

Kathy M Marker

http://www.w3.org/2001/XMLSchema#string

Lisa S Millar

http://www.w3.org/2001/XMLSchema#string

Stephen D Mikolajczyk

http://www.w3.org/2001/XMLSchema#string

William J Catalona

http://www.w3.org/2001/XMLSchema#string

P304

1017-1025

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1373/CLINCHEM.2003.026823

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

50

http://www.w3.org/2001/XMLSchema#string

P577

2004-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8647300

http://www.w3.org/2001/XMLSchema#string

P698

15054080

http://www.w3.org/2001/XMLSchema#string

P921